Facial Plane BlocksNCT06811493
Comparison of the Efficacy of One Level and Tow Level of Bilateral Thoracic Erector Spinae Plane Block Combined With General Anesthesia in Laparoscopic Bariatric Surgery for Obese Patients: Randomized Controlled Trial
A study testing bilateral thoracic erector spinae plane block combined with general anesthesia in laparoscopic bariatric surgery in obese patients in people with Facial Plane Blocks, run by Kasr El Aini Hospital at 1 site in Egypt.
Trial summary
comparison of the feasibility and efficacy of the one-level and two-level thoracic ESP block and their effect on intraoperative and postoperative analgesia in bariatric surgeries. Read more about this study
- Who is it for?
- Ages 18 to 60 yearsHealthy volunteers can take part
- Conditions the study is for
- Facial Plane Blocks
- What is being tested?
- bilateral thoracic erector spinae plane block combined with general anesthesia in laparoscopic bariatric surgery in obese patients
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Jun 2024to 24 Feb 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- • Patient age ranges 18 to 60 years old
- Obese patients ; Body mass index(BMI) ≥ 35 - 50 kg/m2
- American Society of Anesthesiologists (ASA) physical status classes II to III
- Patients scheduled for laparoscopic bariatric surgery i.e. sleeve gastrectomy and/or Roux-en-Y gastric bypass (RYGB) surgeries
Who cannot join
- • Refusal of regional block
- Patients with neurological, psychological disorders or those lacking cooperation
- Patients scheduled for concomitant laparoscopic cholecystectomy or paraumbilical hernia repair or those with history of previous bariatric surgery or obstructive sleep apnea
- Patients with anatomic abnormalities at site of injection, skin lesions or wounds at site of proposed needle insertion.
- Patients with bleeding disorders defined as (INR >1.4) and/ or (platelet count <100,000/µL)
- Patients with hepatic disease e.g. liver cell failure or hepatic malignancy or hepatic enlargement.
- Patients who are allergic to amide local anesthetics.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Comparison of the Efficacy of One Level and Two Level of Bilateral Thoracic Erector Spinae Plane Block Combined With General Anesthesia in Laparoscopic Bariatric Surgery for Obese Patients: Randomized Controlled Trial.
comparison of the feasibility and efficacy of the one-level and two-level thoracic ESP block and their effect on intraoperative and postoperative analgesia in bariatric surgeries.
Read the detailed description
Following approval from Ethics and Research Committee of Anaesthesia Department, Faculty of Medicine, Cairo University; 70 patients fulfilling inclusion criteria will be included in this randomized prospective comparative trial.
A.preoperative:
History will be taken from all patients. Age and then American Society Anaesthesiologists' (ASA) score will be recorded.
Preoperatively patients' laboratory investigations as complete blood picture, coagulation profile, liver and renal functions will be recorded. General examination will be carried out with examination of the back to exclude infection at the injection site and anatomical deformities.
Baseline vital signs will be recorded including non-invasive measurement of systolic, mean, diastolic arterial pressures, and HR and oxygen saturation. After inserting an intravenous (IV) access, the patient will be pre-medicated with metoclopramide in a dose 0.1-0.2 mg/kg.
Patient will be randomly assigned into 1 of 2 groups according to the intervention used whether:
- Group B (Bilevel block) (30 patients): T5 and T10 Erector Spinae block.
- Group O (One level block) (30 patients): T7 Erector Spinae block . Upon arrival to O.R; perioperative monitoring including continuous electrocardiogram (GE-Datex Ohmeda 5 leads ECG cable), pulse oximetry (GE- Datex Ohmeda finger SpO2 sensor), non-invasive arterial blood pressure (GE-Datex Ohmeda NIBP cuff) will be applied.
The block will be performed preoperatively with 1mg midazolam administration intravenous , and 4 cm lidocaine 1% infiltration at each site of block needle prior to the block
In group B, (Bilevel) the block will be performed by the primary investigator . the patient will be placed in the lateral or sitting position . Then, the Erector Spinae block will be given by a high-frequency linear ultrasound transducer of Siemens acuson x300 4.0 - 11.4 MHz ultrasound . It will be sagittally placed against the target vertebral level (T5 transverse process ) (11) in the lateral or sitting position and moved in approximately 3-cm lateral to the spinous process . The Erector Spinae muscle and transverse process will be then identified, and a blunted tip ,100mm, 20-gauge, short bevel needle (Pajunk Sonoplex, Geisingen, Germany) will be advanced, using the in-plane approach, in caudal -to- cephalad direction, through the interfascial plane between the Erector Spinae and the underlying transverse process under strict aseptic precautions until the tip is deep to erector spinae muscle, as evidenced by visible hydro-dissection below the muscle plane, and on injection of 3 ml normal saline to confirm the correct needle tip position and the same technique will be performed at T10 transverse process. The block will be performed bilaterally by injecting 60 mL of 0.25% bupivacaine (15 mL into each of four site) into the fascial plane between the deep surface of the Erector Spinae muscle and the bilateral transverse processes of the thoracic vertebrae 5 and 10 (at the most lateral part of the transverse process) In Group (O) One level The block will be performed bilaterally by injecting 60 mL of 0.25% bupivacaine (30 mL into each side) (12) into the fascial plane between the deep surface of the Erector Spinae muscle and the bilateral transverse processes of the T7 vertebrae by the same technique .
B.intraoperative:
Then, general anaesthesia will be induced in both groups . 1-2 μg/kg fentanyl based on lean body weight (13) with maximum dose of 200 μg and 2 mg/kg propofol will be given based on total body weight (13). Tracheal intubation will be facilitated with 0.5 mg/kg atracurium based on ideal body weight (14).
Anaesthesia will be maintained using isoflurane in oxygen and air. Additional doses of 0.1 mg/kg atracurium will be administrated every 30 minutes. The surgical intervention will be then allowed 20 minutes after finishing the block procedure.
Pressure control volume guarantee ventilation will be adjusted to maintain normocapnia. Anesthesia will be maintained by using 1-1.5% isoflurane in a mixture of oxygen and air (50/50) and atracurium top ups at a dose of 0.1mg/kg every 30 minutes.
All participants will be given 1 gram of intravenous paracetamol every 8 hours Failed block ( increase in HR and mean arterial blood pressure (MABP)>20% from base line with skin incision) will be treated by 1ug /kg of fentanyl as top-up doses and increasing isoflurane concentration in case of inadequate response to fentanyl.
After skin closure, inhalational anesthesia will be discontinued and reversal of muscle relaxation with atropine (0.02 mg/Kg) and neostigmine (0.05 mg/Kg) will be administered intravenous after return of patient's spontaneous breathing. Patients will then be transferred to post anesthesia care unit (PACU) for 60 min to complete recovery and monitoring.
At any time hypotension (defined as a decrease in mean arterial pressure (MAP) >20% from baseline value or systolic arterial pressure (SAP <100 mmHg) will be treated with 5 mg IV bolus ephedrine and repeated every 3 minutes until the hypotension resolved. Bradycardia (defined as a HR less than 15 to 20% of baseline ) will be treated with atropine 0.5 mg IV.(15)
C.postoperative:
In the PACU; VAS will be assessed 30 min after extubation, ketorolac 0.5mg/kg/ 6 hours if VAS score > 3 as first rescue analgesia and nalbuphine as second rescue analgesia 0.1 mg/kg /8 hours as long as the pain score is more than 3\10 ( reassessment to be done after 30 mins of administration of first rescue analgesia ) when the score exceeds 3/10, rescue analgesia in the form of nalbuphine 0.1 mg/Kg will be given. Another dose of nalbuphine 0.1 mg/kg can be given in the PACU if the score still more than 3 after 30 min of the 1st dose with maximum dose of 30 mg every 24 hours.
After discharging from the PACU, the analgesic plan will be intravenous paracetamol one gram every 8 hours , ketorolac 0.5mg/kg/ 6 hours if VAS score > 3 as first rescue analgesia and nalbuphine as second rescue analgesia 0.1 mg/kg /8 hours as long as the pain score is more than 3\10 ( reassessment to be done after 30 mins of administration of first rescue analgesia ).
- Conditions
- Facial Plane Blocks
- Being tested
- bilateral thoracic erector spinae plane block combined with general anesthesia in laparoscopic bariatric surgery in obese patients
- Keywords
- erector spinae plane block, bariatric surgery, obese patients
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
bilateral thoracic erector spinae plane block combined with general anesthesia in laparoscopic bariatric surgery in obese patientsProcedure or surgery
using the in-plane approach, in caudal -to- cephalad direction, through the interfascial plane between the Erector Spinae and the underlying transverse process under strict aseptic precautions until the tip is deep to erector spinae muscle. the block will be performed bilaterally by injecting 60 mL of 0.25% bupivacaine (15 mL into each of four site) into the fascial plane between the deep surface of the Erector Spinae muscle and the bilateral transverse processes of the thoracic vertebrae 5 and 10 (at the most lateral part of the transverse process)
| Study group | Role | What they receive |
|---|---|---|
| two levels of bilateral thoracic erector spinae plane block | Active comparator | two level of bilateral thoracic erector spinae plane block combined with general anesthesia in laparoscopic bariatric Surgery for obese patients Receives: Procedure: bilateral thoracic erector spinae plane block combined with general anesthesia in laparoscopic bariatric surgery in obese patients |
| one level of bilateral thoracic erector spinae plane block | Active comparator | one level of bilateral thoracic erector spinae plane block combined with general anesthesia in laparoscopic bariatric Surgery for obese patients Receives: Procedure: bilateral thoracic erector spinae plane block combined with general anesthesia in laparoscopic bariatric surgery in obese patients |
What is being measured
The primary outcome is the main question the study is designed to answer.
• visual analog scale (VAS) scores during first 24 hour postoperative
Pain will be classified as mild (VAS 1-3), moderate (VAS 4-6), and severe (VAS 7-10) .
Measured: post-operative period at 1 h (hour) , 2 h, 4 h, 8h, 12h,18h and 24 h (hours).
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Feb 2025
- Study start1 Jun 2024
- Primary completion31 Dec 2025
- Study completion24 Feb 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Facial Plane BlocksStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 60 participants (actual)
Sponsor and investigators
- Lead sponsor
- Kasr El Aini Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Emad Mohamed Ahmed Abdelhafez, Kasr El Aini Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06811493
- Sponsor's protocol ID
- MD-407-2024
- Status last verified
- Apr 2026
- First submitted
- 31 Jan 2025
- Last updated
- 22 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 22 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparison of the Efficacy of One Level and Two Level of Bilateral Thoracic Erector Spinae Plane Block Combined With General Anesthesia in Laparoscopic Bariatric Surgery for Obese Patients: Randomized Controlled Trial.
- ClinicalTrials.gov ID
- NCT06811493
- Acronym / sponsor ID
- MD-407-2024
- Conditions
- Facial Plane Blocks
- Keywords
- erector spinae plane block, bariatric surgery, obese patients
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 60 participants (actual)
- Lead sponsor
- Kasr El Aini HospitalUniversity, hospital or other
- Study start
- 1 Jun 2024 (actual)
- Primary completion
- 31 Dec 2025 (actual)
- Study completion
- 24 Feb 2026 (actual)
- First posted
- 6 Feb 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
comparison of the feasibility and efficacy of the one-level and two-level thoracic ESP block and their effect on intraoperative and postoperative analgesia in bariatric surgeries.
Detailed description
Following approval from Ethics and Research Committee of Anaesthesia Department, Faculty of Medicine, Cairo University; 70 patients fulfilling inclusion criteria will be included in this randomized prospective comparative trial.
A.preoperative:
History will be taken from all patients. Age and then American Society Anaesthesiologists' (ASA) score will be recorded.
Preoperatively patients' laboratory investigations as complete blood picture, coagulation profile, liver and renal functions will be recorded. General examination will be carried out with examination of the back to exclude infection at the injection site and anatomical deformities.
Baseline vital signs will be recorded including non-invasive measurement of systolic, mean, diastolic arterial pressures, and HR and oxygen saturation. After inserting an intravenous (IV) access, the patient will be pre-medicated with metoclopramide in a dose 0.1-0.2 mg/kg.
Patient will be randomly assigned into 1 of 2 groups according to the intervention used whether:
- Group B (Bilevel block) (30 patients): T5 and T10 Erector Spinae block.
- Group O (One level block) (30 patients): T7 Erector Spinae block . Upon arrival to O.R; perioperative monitoring including continuous electrocardiogram (GE-Datex Ohmeda 5 leads ECG cable), pulse oximetry (GE- Datex Ohmeda finger SpO2 sensor), non-invasive arterial blood pressure (GE-Datex Ohmeda NIBP cuff) will be applied.
The block will be performed preoperatively with 1mg midazolam administration intravenous , and 4 cm lidocaine 1% infiltration at each site of block needle prior to the block
In group B, (Bilevel) the block will be performed by the primary investigator . the patient will be placed in the lateral or sitting position . Then, the Erector Spinae block will be given by a high-frequency linear ultrasound transducer of Siemens acuson x300 4.0 - 11.4 MHz ultrasound . It will be sagittally placed against the target vertebral level (T5 transverse process ) (11) in the lateral or sitting position and moved in approximately 3-cm lateral to the spinous process . The Erector Spinae muscle and transverse process will be then identified, and a blunted tip ,100mm, 20-gauge, short bevel needle (Pajunk Sonoplex, Geisingen, Germany) will be advanced, using the in-plane approach, in caudal -to- cephalad direction, through the interfascial plane between the Erector Spinae and the underlying transverse process under strict aseptic precautions until the tip is deep to erector spinae muscle, as evidenced by visible hydro-dissection below the muscle plane, and on injection of 3 ml normal saline to confirm the correct needle tip position and the same technique will be performed at T10 transverse process. The block will be performed bilaterally by injecting 60 mL of 0.25% bupivacaine (15 mL into each of four site) into the fascial plane between the deep surface of the Erector Spinae muscle and the bilateral transverse processes of the thoracic vertebrae 5 and 10 (at the most lateral part of the transverse process) In Group (O) One level The block will be performed bilaterally by injecting 60 mL of 0.25% bupivacaine (30 mL into each side) (12) into the fascial plane between the deep surface of the Erector Spinae muscle and the bilateral transverse processes of the T7 vertebrae by the same technique .
B.intraoperative:
Then, general anaesthesia will be induced in both groups . 1-2 μg/kg fentanyl based on lean body weight (13) with maximum dose of 200 μg and 2 mg/kg propofol will be given based on total body weight (13). Tracheal intubation will be facilitated with 0.5 mg/kg atracurium based on ideal body weight (14).
Anaesthesia will be maintained using isoflurane in oxygen and air. Additional doses of 0.1 mg/kg atracurium will be administrated every 30 minutes. The surgical intervention will be then allowed 20 minutes after finishing the block procedure.
Pressure control volume guarantee ventilation will be adjusted to maintain normocapnia. Anesthesia will be maintained by using 1-1.5% isoflurane in a mixture of oxygen and air (50/50) and atracurium top ups at a dose of 0.1mg/kg every 30 minutes.
All participants will be given 1 gram of intravenous paracetamol every 8 hours Failed block ( increase in HR and mean arterial blood pressure (MABP)>20% from base line with skin incision) will be treated by 1ug /kg of fentanyl as top-up doses and increasing isoflurane concentration in case of inadequate response to fentanyl.
After skin closure, inhalational anesthesia will be discontinued and reversal of muscle relaxation with atropine (0.02 mg/Kg) and neostigmine (0.05 mg/Kg) will be administered intravenous after return of patient's spontaneous breathing. Patients will then be transferred to post anesthesia care unit (PACU) for 60 min to complete recovery and monitoring.
At any time hypotension (defined as a decrease in mean arterial pressure (MAP) >20% from baseline value or systolic arterial pressure (SAP <100 mmHg) will be treated with 5 mg IV bolus ephedrine and repeated every 3 minutes until the hypotension resolved. Bradycardia (defined as a HR less than 15 to 20% of baseline ) will be treated with atropine 0.5 mg IV.(15)
C.postoperative:
In the PACU; VAS will be assessed 30 min after extubation, ketorolac 0.5mg/kg/ 6 hours if VAS score > 3 as first rescue analgesia and nalbuphine as second rescue analgesia 0.1 mg/kg /8 hours as long as the pain score is more than 3\10 ( reassessment to be done after 30 mins of administration of first rescue analgesia ) when the score exceeds 3/10, rescue analgesia in the form of nalbuphine 0.1 mg/Kg will be given. Another dose of nalbuphine 0.1 mg/kg can be given in the PACU if the score still more than 3 after 30 min of the 1st dose with maximum dose of 30 mg every 24 hours.
After discharging from the PACU, the analgesic plan will be intravenous paracetamol one gram every 8 hours , ketorolac 0.5mg/kg/ 6 hours if VAS score > 3 as first rescue analgesia and nalbuphine as second rescue analgesia 0.1 mg/kg /8 hours as long as the pain score is more than 3\10 ( reassessment to be done after 30 mins of administration of first rescue analgesia ).
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| two levels of bilateral thoracic erector spinae plane block | Active comparator | Procedure: bilateral thoracic erector spinae plane block combined with general anesthesia in laparoscopic bariatric surgery in obese patientstwo level of bilateral thoracic erector spinae plane block combined with general anesthesia in laparoscopic bariatric Surgery for obese patients |
| one level of bilateral thoracic erector spinae plane block | Active comparator | Procedure: bilateral thoracic erector spinae plane block combined with general anesthesia in laparoscopic bariatric surgery in obese patientsone level of bilateral thoracic erector spinae plane block combined with general anesthesia in laparoscopic bariatric Surgery for obese patients |
Who may qualify
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (4 listed)
- • Patient age ranges 18 to 60 years old
Key exclusion criteria (7 listed)
- • Refusal of regional block
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| bilateral thoracic erector spinae plane block combined with general anesthesia in laparoscopic bariatric surgery in obese patientsusing the in-plane approach, in caudal -to- cephalad direction, through the interfascial plane between the Erector Spinae and the underlying transverse process under strict aseptic precautions until the tip is deep to erector spinae muscle. the block will be performed bilaterally by injecting 60 mL of 0.25% bupivacaine (15 mL into each of four site) into the fascial plane between the deep surface of the Erector Spinae muscle and the bilateral transverse processes of the thoracic vertebrae 5 and 10 (at the most lateral part of the transverse process) | Procedure or surgery | one level of bilateral thoracic erector spinae plane block, two levels of bilateral thoracic erector spinae plane block |
Primary outcome
• visual analog scale (VAS) scores during first 24 hour postoperative
Time frame: post-operative period at 1 h (hour) , 2 h, 4 h, 8h, 12h,18h and 24 h (hours).
Pain will be classified as mild (VAS 1-3), moderate (VAS 4-6), and severe (VAS 7-10) .
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Apr 2026.
- Individual participant dataSharing planned: No
Related trials for Facial Plane Blocks
Not yet recruiting
Comparıson of Analgesıc Effıcacy of Dıfferent Volumes of Serratus Posterior Superıor Intercostal Plane Block After Modıfıed Radıcal Mastectomy Surgery
Modified Radical Mastectomy, Post Operative Pain, Acute
Active, not recruitingObservational study
Effects Of Quadratus Lumborum Type 1 Block And Transversalis Facial Plane Block On Acute Pain In Gynecological Surgery
Postoperative Pain, Gynecologic Surgery
Enrolling by invitation
Serratus Posterior Superior Intercostal Plane Block, Versus Erector Spinae Facial Plane Blocks
Breast Surgery
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing bilateral thoracic erector spinae plane block combined with general anesthesia in laparoscopic bariatric surgery in obese patients in people with Facial Plane Blocks, run by Kasr El Aini Hospital at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 22 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
• visual analog scale (VAS) scores during first 24 hour postoperative (time frame: post-operative period at 1 h (hour) , 2 h, 4 h, 8h, 12h,18h and 24 h (hours).). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Apr 2026.